jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

IHC PANEL with Reporting (Gastrointestinal Neoplasm)

Cancer
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Tumor immunohistochemistry panels.

₹8,880₹12,686

30% OFF

IHC PANEL with Reporting (Gastrointestinal Neoplasm) - Comprehensive Guide

  • Section 1: Why is it done?
    • Test Purpose: Immunohistochemistry (IHC) panel is performed on tissue samples obtained from gastrointestinal neoplasms to identify specific tumor markers and protein expressions. This molecular pathology test uses antibodies to detect antigens in tumor cells, facilitating accurate diagnosis, classification, and treatment planning.
    • Primary Indications: • Diagnosis and classification of gastric cancer, esophageal cancer, colorectal cancer, and pancreatic neoplasms • Determination of tumor type, grade, and differentiation status • Assessment of prognostic factors to guide treatment decisions • Identification of specific tumor markers for targeted therapy eligibility • Differentiation between primary gastrointestinal malignancy and metastatic disease • Evaluation of cellular differentiation and cellular origin
    • Typical Timing & Circumstances: • Performed immediately after endoscopic or surgical tissue biopsy • Typically completed within 1-2 weeks of tissue collection • Conducted on formalin-fixed, paraffin-embedded tissue samples • Essential component of initial tumor characterization following histological diagnosis • May be repeated if recurrent or metastatic disease is suspected
  • Section 2: Normal Range
    • Reference Values & Interpretation: • IHC results are reported as POSITIVE or NEGATIVE staining patterns • No numerical reference ranges apply; results are qualitative • Positive result (1+ to 3+): Indicates presence of specific antigen/protein • Negative result: Indicates absence or minimal expression of target protein • Expression intensity graded on 0-3+ scale: - 0: No staining (Negative) - 1+: Weak staining (Positive, weak) - 2+: Moderate staining (Positive, moderate) - 3+: Strong staining (Positive, strong)
    • Percentage of Positive Cells: • <5%: Negative • 5-25%: Positive, weak/focal • 25-50%: Positive, moderate • >50%: Positive, diffuse
    • Common Gastrointestinal Panel Markers: • CEA (Carcinoembryonic Antigen): Normal = Negative; Positive indicates adenocarcinoma • CK7 (Cytokeratin 7): Helps differentiate tumor origin • CK20 (Cytokeratin 20): Assists in determining primary tumor site • HER2/neu: Positive indicates eligibility for targeted therapy • MSI (Microsatellite Instability): Positive indicates mismatch repair deficiency • PD-L1 (Programmed Death Ligand-1): Determines immunotherapy candidacy • EGFR (Epidermal Growth Factor Receptor): Presence guides targeted treatment
    • Normal vs. Abnormal Interpretation: • Normal (Non-neoplastic tissue): Shows minimal or absent staining for tumor-associated markers • Abnormal: Demonstrates positive staining patterns consistent with malignant transformation and specific tumor type characterization
  • Section 3: Interpretation
    • Adenocarcinoma Pattern (CEA+, CK7+, CK20+): • Indicates primary gastrointestinal adenocarcinoma • Associated with colorectal and gastric origins • Suggests glandular epithelial differentiation
    • HER2/neu Positive Status: • Indicates patient eligibility for HER2-targeted therapy (trastuzumab, pertuzumab) • Associated with more aggressive tumor behavior • Approximately 10-15% of gastric and esophageal cancers are HER2 positive • Confers both therapeutic opportunity and potential prognostic implications
    • Microsatellite Instability (MSI) High/Positive: • Indicates mismatch repair (MMR) gene deficiency • Associated with Lynch syndrome or sporadic hypermethylation • Predictor of immunotherapy responsiveness • Patients may benefit from checkpoint inhibitor therapy • Increased risk of additional malignancies
    • PD-L1 Positive Expression: • Indicates patient candidacy for PD-L1 or PD-1 checkpoint inhibitor therapy • 40-50% of gastric cancers express PD-L1 • Expression correlates with potential therapeutic response • May indicate immune-evasive tumor phenotype
    • Squamous Cell Pattern (p63+, SOX2+): • Indicates squamous cell carcinoma differentiation • Common in esophageal malignancies • Associated with different therapeutic considerations than adenocarcinomas
    • Neuroendocrine Pattern (Chromogranin A+, Synaptophysin+): • Indicates neuroendocrine or neuroendocrine combination differentiation • Associated with different treatment protocols and prognosis • May include somatostatin receptor expression for targeted imaging
    • Factors Affecting Results: • Tissue fixation quality and duration • Antigen retrieval methodology • Primary antibody specificity and quality • Tumor heterogeneity (sampling from different tumor areas may show variation) • Prior treatment effects on antigen expression • Technical variations in staining protocols
  • Section 4: Associated Organs
    • Primary Organ Systems Involved: • Esophagus: Squamous cell and adenocarcinomas • Stomach: Gastric adenocarcinomas, neuroendocrine tumors • Small intestine: Adenocarcinomas, neuroendocrine tumors, lymphomas • Colon and rectum: Colorectal adenocarcinomas • Pancreas: Pancreatic adenocarcinomas, neuroendocrine tumors • Hepatobiliary system: Cholangiocarcinomas, hepatocellular carcinomas
    • Gastrointestinal Neoplasms Identified: • Esophageal squamous cell carcinoma (ESCC) • Gastroesophageal junction adenocarcinoma • Gastric adenocarcinoma (intestinal, diffuse, mixed types) • Gastric neuroendocrine carcinoma • Colorectal adenocarcinoma • High-grade dysplasia and intramucosal carcinoma • Pancreatic ductal adenocarcinoma (PDAC) • Ampullary carcinoma • Cholangiocarcinoma
    • Associated Medical Conditions: • Barrett's esophagus with dysplasia • Intestinal metaplasia of stomach • Chronic atrophic gastritis • Hereditary nonpolyposis colorectal cancer (Lynch syndrome) • Familial adenomatous polyposis (FAP) • Inflammatory bowel disease • Helicobacter pylori infection-associated gastric neoplasia • Chronic pancreatitis with malignant transformation
    • Potential Complications & Risks Associated with Abnormal Results: • Disease progression and metastatic spread (regional lymph nodes, liver, peritoneum) • Peritoneal carcinomatosis in advanced gastric cancer • Hepatic metastases in colorectal and gastric cancers • Aggressive tumor biology requiring intensive multimodal therapy • Treatment-related toxicities (chemotherapy, radiation, immunotherapy side effects) • Secondary malignancy development (Lynch syndrome carriers) • Gastrointestinal obstruction, perforation, bleeding • Fistula formation in advanced disease • Ascites and malignant effusions
    • Prognostic Implications: • HER2 positivity: Variable prognosis, but targeted therapy availability • MSI-high: Generally favorable prognosis but requires immunotherapy consideration • PD-L1 positivity: May indicate immunotherapy responsiveness • Tumor differentiation grade: Poorly differentiated tumors carry worse prognosis • Lymphovascular invasion markers: Indicate aggressive behavior • p53 alterations: Associated with worse outcomes in gastric cancers
  • Section 5: Follow-up Tests
    • Additional Pathology Testing: • Fluorescence In Situ Hybridization (FISH) for HER2 confirmation and gene copy number • Targeted mutation analysis (KRAS, TP53, APC, SMAD4, PIK3CA) • Next-generation sequencing (NGS) for comprehensive genomic profiling • Mismatch repair protein expression (MLH1, MSH2, MSH6, PMS2) by IHC • Tumor mutational burden (TMB) testing for immunotherapy eligibility • DNA methylation profiling for tumor classification
    • Staging and Imaging Follow-up: • Computed tomography (CT) chest, abdomen, and pelvis for metastatic staging • Endoscopic ultrasound (EUS) for locoregional extension assessment • PET-CT scan for metabolic activity and metastatic disease detection • Diagnostic laparoscopy for peritoneal disease evaluation (gastric cancer) • Colonoscopy with complete examination for colorectal cancer complete staging • Magnetic resonance imaging (MRI) for hepatic or peritoneal metastases
    • Serum Tumor Markers: • Carcinoembryonic antigen (CEA) for baseline and surveillance • Cancer antigen 19-9 (CA 19-9) particularly for pancreatic and gastric cancers • Alpha-fetoprotein (AFP) if hepatic involvement suspected • Specific neuroendocrine markers (chromogranin A, NSE) if applicable
    • Genetic Testing & Counseling: • Germline testing for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) • BRCA1/BRCA2 testing for gastric cancer predisposition • Familial adenomatous polyposis (FAP) testing if appropriate • Genetic counseling for carriers and family members • Surveillance recommendations for family members at risk
    • Monitoring Frequency for Treated Disease: • Post-surgical: Surveillance imaging every 3-6 months for first 2 years • During chemotherapy: Assessment per treatment protocol (typically 2-4 weeks) • Post-treatment: Extended surveillance every 3-6 months for years 2-3, then annually • Tumor marker monitoring: Baseline and periodic assessment (3-6 months intervals) • Endoscopic surveillance: As clinically indicated, especially for dysplasia or Barrett's
    • Complementary Diagnostic Information: • Histopathology report review including grade, stage, and margin status • Hematology panel for baseline chemotherapy tolerance assessment • Comprehensive metabolic panel for organ function baseline • Functional capacity evaluation before multimodal therapy • Multidisciplinary tumor board review for treatment planning • Liquid biopsy (circulating tumor DNA) for treatment monitoring and early recurrence detection
  • Section 6: Fasting Required?
    • Fasting Requirement: NO - Fasting is NOT required for IHC panel testing on tissue samples.
    • Explanation: • IHC is performed on fixed tissue samples obtained via biopsy or surgical resection • Tissue samples are fixed in formalin and processed before analysis • Patient metabolic state does not influence staining patterns or results • Fasting status is irrelevant to antigen detection in tissue
    • Preparation for Tissue Biopsy (if obtaining sample): • For endoscopic biopsy: Usually requires fasting 6-8 hours prior to procedure • NPO (nothing by mouth) status: Typically from midnight before morning procedure • Medication adjustments: Aspirin and anticoagulants may require temporary discontinuation • Arrange transportation: Some patients receive sedation for endoscopy • Informed consent: Obtain before biopsy procedure
    • Special Instructions & Precautions: • Medications to potentially avoid before biopsy: - Anticoagulants (warfarin, apixaban, rivaroxaban) - check with provider - Antiplatelet agents (clopidogrel, ticagrelor) - may require temporary cessation - NSAIDs - discontinue 3-5 days before procedure • Notify healthcare provider of: - Bleeding disorders or anticoagulation therapy - Severe portal hypertension - Inability to tolerate sedation • Arrange time off work: Recovery period typically 24 hours post-endoscopy
    • Post-Biopsy Care: • Avoid strenuous activity for 24-48 hours • Monitor for signs of bleeding, perforation, or infection • Report severe abdominal pain, persistent vomiting, or black tarry stools immediately • Resume normal diet gradually as tolerated • Take prescribed medications as directed • Follow-up appointment typically scheduled in 1-2 weeks for results discussion
    • Tissue Processing & Handling: • Tissue must be immediately placed in formalin fixative • Proper fixation duration (typically 6-24 hours) is critical for IHC quality • Samples must be properly labeled with patient identifiers • Temperature stability maintained during transport to laboratory • Tissue processing takes 24-48 hours before IHC can commence • Total turnaround time: 5-10 business days for routine cases (may be expedited)

How our test process works!

customers
customers